CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.1%

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) traded down 0.1% during mid-day trading on Wednesday . The stock traded as low as $52.92 and last traded at $52.92. 301,619 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 1,772,027 shares. The stock had previously closed at $52.99.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. TheStreet upgraded CRISPR Therapeutics from a "d+" rating to a "c" rating in a report on Friday, February 23rd. Mizuho boosted their price objective on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. Citigroup upped their price target on CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a "buy" rating in a report on Thursday, April 18th. Chardan Capital upped their price target on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a "buy" rating in a report on Thursday, February 22nd. Finally, Needham & Company LLC restated a "buy" rating and set a $90.00 price target on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $76.29.

CRISPR Therapeutics Stock Performance

The stock has a market capitalization of $4.57 billion, a price-to-earnings ratio of -27.45 and a beta of 1.76. The business has a 50-day moving average of $69.50 and a 200-day moving average of $64.23.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.15 by $0.95. The firm had revenue of $201.20 million during the quarter, compared to analyst estimates of $148.72 million. The firm's revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same period last year, the company earned ($1.41) earnings per share. On average, research analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 20,000 shares of the company's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the completion of the sale, the chief executive officer now directly owns 187,377 shares of the company's stock, valued at approximately $15,057,615.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other CRISPR Therapeutics news, CFO Raju Prasad sold 3,524 shares of the company's stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.69, for a total transaction of $256,159.56. Following the completion of the sale, the chief financial officer now directly owns 6,476 shares of the company's stock, valued at approximately $470,740.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 20,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $80.36, for a total value of $1,607,200.00. Following the transaction, the chief executive officer now directly owns 187,377 shares of the company's stock, valued at $15,057,615.72. The disclosure for this sale can be found here. Insiders sold a total of 83,992 shares of company stock valued at $6,132,335 in the last three months. 4.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently modified their holdings of CRSP. ARK Investment Management LLC raised its stake in shares of CRISPR Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company's stock worth $534,360,000 after buying an additional 1,372,986 shares in the last quarter. Norges Bank purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $38,661,000. Westfield Capital Management Co. LP purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $13,506,000. Baillie Gifford & Co. raised its stake in shares of CRISPR Therapeutics by 81.1% during the 3rd quarter. Baillie Gifford & Co. now owns 441,063 shares of the company's stock worth $20,020,000 after buying an additional 197,469 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. purchased a new position in CRISPR Therapeutics in the 4th quarter valued at approximately $10,848,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.